Challenges in the development of egg-independent vaccines for influenza

References

• Moreno A, Lelli D, Lavazza A, et al. MAb-based competitive ELISA for the detection of antibodies against influenza D virus. Transbound Emerg Dis. 2019;66(1):268–276.
   PubMed Web of Science ®Google Scholar
• Collin EA, Sheng Z, Lang Y, et al. Cocirculation of two distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J Virol. 2015;89(2):1036–1042.
   PubMed Web of Science ®Google Scholar
• Hause BM, Collin EA, Liu R, et al. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. MBio. 2014;5(2):e00031–14.
   PubMed Web of Science ®Google Scholar
• WHO. Influenza (Seasonal). 2018; Available from: https://www.who.int/health-topics/news-room/fact-sheets/detail/influenza-(seasonal).
   Google Scholar
• Rajao DS, Perez DR. Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. Front Microbiol. 2018;9:123.
   PubMed Web of Science ®Google Scholar
• Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17(3):295–300.
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3.
   PubMed Web of Science ®Google Scholar
• Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476–492.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–88.
   PubMed Web of Science ®Google Scholar
• Allen JD, Ross TM. H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018;14(8):1840–1847.
   PubMed Web of Science ®Google Scholar
• Marshall N, Priyamvada L, Ende Z, et al. Influenza virus reassortment occurs with high frequency in the absence of segment mismatch. PLoS Pathog. 2013;9(6):e1003421.
   PubMed Web of Science ®Google Scholar
• Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines (Basel). 2018;6(2):1–12.
   PubMed Web of Science ®Google Scholar
• Boivin S, Cusack S, Ruigrok RW, et al. Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem. 2010;285(37):28411–28417.
   PubMed Web of Science ®Google Scholar
• Ping J, Lopes TJ, Nidom CA, et al. Development of high-yield influenza A virus vaccine viruses. Nat Commun. 2015;6:8148.
   PubMed Web of Science ®Google Scholar
• Onions D, Egan W, Jarrett R, et al. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals. 2010;38(5):544–551.
   PubMed Web of Science ®Google Scholar
• Squeri R, Riso R, Facciola A, et al. Management of two influenza vaccination campaign in health care workers of a university hospital in the south Italy. Ann Ig. 2017;29(3):223–231.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15(8):967–976.
   PubMed Web of Science ®Google Scholar
• WHO. A Description of the Process of Seasonal and H5N1 Influenza Vaccine Virus Selection and Development. Geneva; 2007.
   Google Scholar
• Hampson A, Barr I, Cox N, et al. Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine. 2017;35(8):1104–1109.
   PubMed Web of Science ®Google Scholar
• Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016;10(5):354–360.
   PubMed Web of Science ®Google Scholar
• Group WHOW, Ampofo WK, Baylor N, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses. 2012;6(2):142–52, e1-5.
   Web of Science ®Google Scholar
• WHO. Improving influenza vaccine virus selection. Report of the 4th WHO Informal Consultation Hong Kong SAR, China, 18–20 Nov 2015.
   Google Scholar
• ecdc. WHO issues recommendation on the composition of influenza virus vaccines for the northern hemisphere 2015-2016. 2015; Available from: https://ecdc.europa.eu/en/news-events/who-issues-recommendation-composition-influenza-virus-vaccines-northern-hemisphere-2015.
   Google Scholar
• Manini I, Trombetta CM, Lazzeri G, et al. Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines (Basel). 2017;5(3):1–8.
   PubMed Web of Science ®Google Scholar
• Ampofo WK, Azziz-Baumgartner E, Bashir U, et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine. 2015;33(36):4368–4382.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Remarque EJ, Mortier D, et al. Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses. Influenza Other Respir Viruses. 2018;12(6):675–686.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Perini D, Mather S, et al. Overview of Serological Techniques for Influenza Vaccine Evaluation: past, Present and Future. Vaccines (Basel). 2014;2(4):707–734.
   PubMedGoogle Scholar
• FLUCOP. http://www.flucop.eu/.
   Google Scholar
• CONSISE. Available from: https://consise.tghn.org/.
   Google Scholar
• Kilbourne ED, Schulman JL, Schild GC, et al. Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J Infect Dis. 1971;124(5):449–462.
   PubMed Web of Science ®Google Scholar
• Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21(16):1776–1779.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Olsen SJ, Sokolow LZ, et al. C. Centers for Disease, and Prevention, Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) – United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(32):691–697.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Meeting on Live Attenuated Influenza Vaccine Effectiveness. Geneva, 2016;1–3.
   Google Scholar
• Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263.
   PubMed Web of Science ®Google Scholar
• Neurath AR, Rubin BA, Sillaman J, et al. The effect of nonaqueous solvents on the quaternary structure of viruses: a procedure for the simultaneous concentration, purification and disruption of influenza viruses. Microbios. 1971;4(14):145–150.
   PubMedGoogle Scholar
• Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002;20(25–26):3068–3087.
   PubMed Web of Science ®Google Scholar
• Laver WG, Webster RG. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine. Postgrad Med J. 1976;52(608):373–378.
   PubMed Web of Science ®Google Scholar
• Bragazzi NL, Orsi A, Ansaldi F, et al. Fluzone(R) intra-dermal (Intanza(R)/Istivac(R) Intra-dermal): an updated overview. Hum Vaccin Immunother. 2016;12(10):2616–2627.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strategies: comparing Inactivated and live attenuated influenza vaccines. Vaccines (Basel). 2015;3(2):373–389.
   PubMed Web of Science ®Google Scholar
• Manini I, Domnich A, Amicizia D, et al. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines. 2015;14(6):789–804.
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20(Suppl 5):B17–23.
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Kunzi V, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(33):4381–4387.
   PubMed Web of Science ®Google Scholar
• Moser C, Muller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–791.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29(9):806–811.
   PubMed Web of Science ®Google Scholar
• WHO. PUBLIC ASSESSMENT SUMMARY REPORT– NASOVAC-S. Geneva, 2015;1–2.
   Google Scholar
• EMA. EPAR summary for the public. 2014. European Medicines Agency. EMA/37738/2014. EMEA/H/C/001101.
   Google Scholar
• Desheva Y. Preparing Live Influenza Vaccine against potential pandemic influenza using nonpathogenic avian influenza viruses and cold-adapted master donor strain. In: Saxena SK, editor. Influenza Therapeucis and Challenges. London: IntechOpen; 2018. p. 59–80.
   Google Scholar
• Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12(5):519–536.
   PubMed Web of Science ®Google Scholar
• Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines. 2010;9(12):1423–1439.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685–696.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845–853.
   PubMed Web of Science ®Google Scholar
• Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986;24(1):157–160.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine. 1999;17(15–16):1905–1909.
   PubMed Web of Science ®Google Scholar
• Barberis I, Myles P, Ault SK, et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016;57(3). E115–E120.
   PubMedGoogle Scholar
• Protein Sciences. Superior Protection by Flublok® Influenza Vaccine in Seniors Documented in New England Journal of Medicine. Meriden, CT; 2017.
   Google Scholar
• CDC. Recombinant Influenza (Flu) Vaccine. 2018; Available from: https://www.cdc.gov/flu/protect/vaccine/qa_flublok-vaccine.htm.
   Google Scholar
• eCDC. Seasonal influenza vaccine produced using recombinant technology approved for use in North America. 2013; Available from: https://ecdc.europa.eu/en/news-events/seasonal-influenza-vaccine-produced-using-recombinant-technology-approved-use-north.
   Google Scholar
• Zhou F, Trieu MC, Davies R, et al. Improving influenza vaccines: challenges to effective implementation. Curr Opin Immunol. 2018;53:88–95.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29(44):7733–7739.
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011;29(12):2272–2278.
   PubMed Web of Science ®Google Scholar
• Buckland B, Boulanger R, Fino M, et al. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine. 2014;32(42):5496–5502.
   PubMed Web of Science ®Google Scholar
• Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses. 2008;2(6):211–219.
   PubMed Web of Science ®Google Scholar
• Perez Rubio A, Eiros JM. Cell culture-derived flu vaccine: present and future. Hum Vaccin Immunother. 2018;14(8):1874–1882.
   PubMed Web of Science ®Google Scholar
• Montomoli E, Khadang B, Piccirella S, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev Vaccines. 2012;11(5):587–594.
   PubMed Web of Science ®Google Scholar
• Pandey A, Singh N, Sambhara S, et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin. 2010;6(2):178–188.
   PubMed Web of Science ®Google Scholar
• Hegde NR. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hum Vaccin Immunother. 2015;11(5):1223–1234.
   PubMed Web of Science ®Google Scholar
• Buckland BC. The development and manufacture of influenza vaccines. Hum Vaccin Immunother. 2015;11(6):1357–1360.
   PubMed Web of Science ®Google Scholar
• Lee YT, Kim KH, Ko EJ, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014;3(1):12–28.
   PubMedGoogle Scholar
• CDC. Use of Influenza A (H1N1) 2009 Monovalent Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. Recommendations and Reports. August 28, 2009 / 58(RR10);1–8.
   Google Scholar
• Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010;363(21):2036–2044.
   PubMed Web of Science ®Google Scholar
• Romanova J. Influenza vaccines manufacturing in continuous cell lines: problems and solutions. Mir J. 2017;4(1):1–9.
   Google Scholar
• Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine. 2008;26(26):3332–3340.
   PubMed Web of Science ®Google Scholar
• WHO. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull World Health Organ. 1995;73(4):431–435.
   PubMed Web of Science ®Google Scholar
• Oxford JS, Corcoran T, Knott R, et al. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull World Health Organ. 1987;65(2):181–187.
   PubMed Web of Science ®Google Scholar
• Robertson JS, Cook P, Attwell AM, et al. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine. 1995;13(16):1583–1588.
   PubMed Web of Science ®Google Scholar
• Gambaryan AS, Robertson JS, Matrosovich MN. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology. 1999;258(2):232–239.
   PubMed Web of Science ®Google Scholar
• Schulze IT. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis. 1997;176(Suppl 1):S24–8.
   PubMedGoogle Scholar
• Oxford JS, Newman R, Corcoran T, et al. Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition. J Gen Virol. 1991;72(Pt 1):185–189.
   PubMedGoogle Scholar
• Robertson JS, Naeve CW, Webster RG, et al. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology. 1985;143(1):166–174.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.
   PubMed Web of Science ®Google Scholar
• Meyer WJ, Wood JM, Major D, et al. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology. 1993;196(1):130–137.
   PubMed Web of Science ®Google Scholar
• Oxford JS, Schild GC, Corcoran T, et al. A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers. Arch Virol. 1990;110(1–2):37–46.
   PubMed Web of Science ®Google Scholar
• Zuckerman MA, Cox RJ, Oxford JS. Attenuation of virulence in influenza B viral infection of volunteers. J Infect. 1994;28(1):41–48.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhou H, Jin H. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine. 2010;28(24):4079–4085.
   PubMed Web of Science ®Google Scholar
• Robertson JS, Bootman JS, Newman R, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology. 1987;160(1):31–37.
   PubMed Web of Science ®Google Scholar
• Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology. 1987;156(2):386–395.
   PubMed Web of Science ®Google Scholar
• James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133(5):624–628.
   PubMed Web of Science ®Google Scholar
• Croegaert KA, Ithman MM, Spurgin AL, et al. Influenza vaccine safety in patients with egg allergy. J Am Pharm Assoc (2003). 2013;53(2):214–216.
   PubMed Web of Science ®Google Scholar
• Greenhawt M. Live attenuated influenza vaccine for children with egg allergy. BMJ. 2015;351:h6656.
   PubMedGoogle Scholar
• Sicherer SH. Epidemiology of food allergy. J Allergy Clin Immunol. 2011;127(3):594–602.
   PubMed Web of Science ®Google Scholar
• Milian E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:504831.
   PubMed Web of Science ®Google Scholar
• Perdue ML, Arnold F, Li S, et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines. 2011;10(8):1183–1194.
   PubMed Web of Science ®Google Scholar
• Bernstein DI. Cell culture-derived influenza vaccines: has their time come? Clin Infect Dis. 2010;51(9):1005–1006.
   PubMed Web of Science ®Google Scholar
• Yusibov V, Rabindran S. Recent progress in the development of plant derived vaccines. Expert Rev Vaccines. 2008;7(8):1173–1183.
   PubMed Web of Science ®Google Scholar
• Madin SH, Darby NB Jr. Established kidney cell lines of normal adult bovine and ovine origin. Proc Soc Exp Biol Med. 1958;98(3):574–576.
   PubMed Web of Science ®Google Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines. 2009;8(12):1681–1692.
   PubMed Web of Science ®Google Scholar
• Roth B, Mohr H, Enders M, et al. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine. 2012;30(3):517–522.
   PubMed Web of Science ®Google Scholar
• Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009;200(6):841–848.
   PubMed Web of Science ®Google Scholar
• Youil R, Su Q, Toner TJ, et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods. 2004;120(1):23–31.
   PubMed Web of Science ®Google Scholar
• Merten OW, Hannoun C, Manuguerra JC, et al. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol. 1996;397:141–151.
   PubMedGoogle Scholar
• Tree JA, Richardson C, Fooks AR, et al. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine. 2001;19(25–26):3444–3450.
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Sugawara K, Nouchi T, et al. Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologicals. 2008;36(2):122–133.
   PubMed Web of Science ®Google Scholar
• Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418–8425.
   PubMed Web of Science ®Google Scholar
• Oh DY, Barr IG, Mosse JA, et al. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008;46(7):2189–2194.
   PubMed Web of Science ®Google Scholar
• Abdoli A, Soleimanjahi H, Jamali A, et al. Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production. Biotechnol Lett. 2016;38(6):941–948.
   PubMed Web of Science ®Google Scholar
• Wood JM, Oxford JS, Dunleavy U, et al. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology. 1989;171(1):214–221.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis. 2009;200(6):849–857.
   PubMed Web of Science ®Google Scholar
• Oxford JS, Al-Jabri AA, Lambkin R, et al. Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine. Vaccine. 2003;21(21–22):2743–2746.
   PubMed Web of Science ®Google Scholar
• Shin D, Park KJ, Lee H, et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Virus Res. 2015;204:40–46.
   PubMed Web of Science ®Google Scholar
• Seqirus. Seqirus announces next major advancement in cell-based influenza vaccine technology. Holly Springs, NC; 2017.
   Google Scholar
• Barr IG, Donis RO, Katz JM, et al. Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:44.
   PubMed Web of Science ®Google Scholar
• Buhler S, Ramharter M. Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures. ESMO Open. 2019;4(1):e000481.
   PubMed Web of Science ®Google Scholar
• Flannery B, Fry AM. Comparing influenza vaccine types: the path towards improved influenza vaccine strategies. J Infect Dis. 2018.
   Google Scholar
• Govorkova EA, Murti G, Meignier B, et al. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol. 1996;70(8):5519–5524.
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Kaverin NV, Gubareva LV, et al. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis. 1995;172(1):250–253.
   PubMed Web of Science ®Google Scholar
• Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand. 1981;47:55–64.
   PubMedGoogle Scholar
• Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol. 1968;2(10):955–961.
   PubMed Web of Science ®Google Scholar
• EMA. Questions and answers on the review of Preflucel and associated names (influenza vaccine, purified antigen). 2012. European Medicines Agency. 19 July 2012 EMA/CHMP/475586/2012 EMEA/H/A-36/1323. London, UK.
   Google Scholar
• Kistner O, Barrett PN, Mundt W, et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine. 1998;16(9–10):960–968.
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Berezuk G, Fritsch S, et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine. 2012;30(29):4377–4386.
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Singer J, Berezuk G, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis. 2012;54(7):946–954.
   PubMed Web of Science ®Google Scholar
• Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011;377(9767):751–759.
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9(13):1909–1917.
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, et al. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine. 2001;19(17–19):2716–2721.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009;27(13):1889–1897.
   PubMed Web of Science ®Google Scholar
• Hasson SSAA, Al-Busaidi JKZ, Sallam TA. The past, current and future trends in DNA vaccine immunisations. Asian Pac J Trop Biomed. 2015;5(5):344–353.
   Google Scholar
• WHO. DNA vaccines. 2015. [cited 2019 Mar 24]. Available from: https://www.who.int/biologicals/areas/vaccines/dna/en/.
   Google Scholar
• Bicho D, Queiroz JA, Tomaz CT. Influenza Plasmid DNA Vaccines: progress and Prospects. Curr Gene Ther. 2015;15(6):541–549.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr Top Microbiol Immunol. 2009;333:197–210.
   PubMedGoogle Scholar
• Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.
   PubMed Web of Science ®Google Scholar
• Hoare M, Levy MS, Bracewell DG, et al. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog. 2005;21(6):1577–1592.
   PubMed Web of Science ®Google Scholar
• Prather KJ, Sagar S, Murphy J, et al. .;, Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol. 2003;33:865–883.
   Web of Science ®Google Scholar
• Mor G, Singla M, Steinberg AD, et al. Do DNA vaccines induce autoimmune disease? Hum Gene Ther. 1997;8(3):293–300.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Tross D, et al. FDA guidance on prophylactic DNA vaccines: analysis and recommendations. Vaccine. 2010;28(16):2801–2805.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Sechler JM, Conover J, et al. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol. 1998;160(5):2388–2392.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Conover J, Bloom ET, et al. Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci. 1998;53(4):B281–6.
   PubMed Web of Science ®Google Scholar
• AgriLabs. First DNA Vaccine Licensed for Chickens. 2017. [cited 2019 Mar 05]. Available from: https://www.agrilabs.com/about-us/newsroom/first-dna-vaccine-licensed-for-chickens.
   Google Scholar
• Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 2009;27(18):2506–2512.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011;11(12):916–924.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Bellamy AR, Belshe R, V.R.C.s. team, et al. DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One. 2015;10(5):e0125914.
   PubMed Web of Science ®Google Scholar
• V.R.C.s. team, Houser KV, Yamshchikov GV, Bellamy AR, et al. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS One. 2018;13(11):e0206837.
   PubMed Web of Science ®Google Scholar
• Lee LYY, Izzard L, Hurt AC. A review of DNA vaccines against influenza. Front Immunol. 2018;9:1568.
   PubMed Web of Science ®Google Scholar
• Scorza FB, Pardi N. New kids on the block: RNA-based influenza virus vaccines. Vaccines (Basel). 2018;6(2):1–15.
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother. 2012;8(3):411–414.
   PubMed Web of Science ®Google Scholar
• Chroboczek J, Szurgot I, Szolajska E. Virus-like particles as vaccine. Acta Biochim Pol. 2014;61(3):531–539.
   PubMed Web of Science ®Google Scholar
• Roldao A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9(10):1149–1176.
   PubMed Web of Science ®Google Scholar
• Sedova ES, Shcherbinin DN, Migunov AI, et al. Recombinant influenza vaccines. Acta Naturae. 2012;4(4):17–27.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
   PubMed Web of Science ®Google Scholar
• Sequeira DP, Correia R, Carrondo MJT, et al. Combining stable insect cell lines with baculovirus-mediated expression for multi-HA influenza VLP production. Vaccine. 2018;36(22):3112–3123.
   PubMed Web of Science ®Google Scholar
• Fuenmayor J, Godia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol. 2017;39(Pt B):174–180.
   PubMedGoogle Scholar
• Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(1):244–251.
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81(7):3514–3524.
   PubMed Web of Science ®Google Scholar
• Quan FS, Steinhauer D, Huang C, et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26(26):3352–3361.
   PubMed Web of Science ®Google Scholar
• Inn KS, Lee GJ, Quan FS. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol Invest. 2014;43(3):236–254.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871–3878.
   PubMed Web of Science ®Google Scholar
• Hossain MJ, Bourgeois M, Quan FS, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol. 2011;18(12):2010–2017.
   PubMed Web of Science ®Google Scholar
• Pushko P, Kort T, Nathan M, et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010;28(30):4771–4776.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23(50):5751–5759.
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31(40):4305–4313.
   PubMed Web of Science ®Google Scholar
• Novavax. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference. Geneva, Switzerland; 2010. Available from: http://ir.novavax.com/news-releases/news-release-details/novavax-presents-positive-clinical-results-world-health
   Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol. 2011;85(21):10945–10954.
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011;29(44):7826–7834.
   PubMed Web of Science ®Google Scholar
• Smith GE, Sun X, Bai Y, et al. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets. Virology. 2017;509:90–97.
   PubMed Web of Science ®Google Scholar
• Lico C, Desiderio A, Banchieri S, et al. Plants as biofactories: production of pharmaceutical recombinant proteins. In: Tuberosa R, Phillips RL, Gale M, editors. In the wake of the double helix: from the green revolution to the gene revolution. Proceedings of an International Congress, Bologna; 2005. p. 577–593.
   Google Scholar
• Margolin E, Chapman R, Williamson AL, et al. Production of complex viral glycoproteins in plants as vaccine immunogens. Plant Biotechnol J. 2018;16:1531–1545.
   PubMed Web of Science ®Google Scholar
• Musiychuk K, Stephenson N, Bi H, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses. 2007;1(1):19–25.
   PubMed Web of Science ®Google Scholar
• Mett V, Farrance CE, Green BJ, et al. Plants as biofactories. Biologicals. 2008;36(6):354–358.
   PubMed Web of Science ®Google Scholar
• Komarova TV, Baschieri S, Donini M, et al. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines. 2010;9(8):859–876.
   PubMed Web of Science ®Google Scholar
• Redkiewicz P, Sirko A, Kamel KA, et al. Plant expression systems for production of hemagglutinin as a vaccine against influenza virus. Acta Biochim Pol. 2014;61(3):551–560.
   PubMed Web of Science ®Google Scholar
• Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev Vaccines. 2009;8(4):493–498.
   PubMed Web of Science ®Google Scholar
• Shoji Y, Bi H, Musiychuk K, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine. 2009;27(7):1087–1092.
   PubMed Web of Science ®Google Scholar
• Shoji Y, Chichester JA, Jones M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin. 2011;7(Suppl):41–50.
   PubMed Web of Science ®Google Scholar
• Pillet S, Racine T, Nfon C, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33(46):6282–6289.
   PubMed Web of Science ®Google Scholar
• Hodgins B, Yam KK, Winter K, et al. A single intramuscular dose of a plant-made virus-like particle vaccine elicits a balanced humoral and cellular response and protects young and aged mice from influenza H1N1 virus challenge despite a modest/absent humoral response. Clin Vaccine Immunol. 2017;24(12):1–14.
   PubMed Web of Science ®Google Scholar
• D’Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008;6(9):930–940.
   PubMed Web of Science ®Google Scholar
• Shoji Y, Farrance CE, Bautista J, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses. 2012;6(3):204–210.
   PubMed Web of Science ®Google Scholar
• Shoji Y, Chichester JA, Bi H, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine. 2008;26(23):2930–2934.
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5(12):e15559.
   PubMed Web of Science ®Google Scholar
• Chichester JA, Jones RM, Green BJ, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses. 2012;4(11):3227–3244.
   PubMed Web of Science ®Google Scholar
• Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine. 2014;32(19):2251–2259.
   PubMed Web of Science ®Google Scholar
• Pillet S, Aubin E, Trepanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72–87.
   PubMed Web of Science ®Google Scholar
• Ortiz JR, Hombach J. Announcing the publication of the WHO immunological basis for immunization series module on influenza vaccines. Vaccine. 2018;36(37):5504–5505.
   PubMed Web of Science ®Google Scholar
• Henry C, Palm AE, Krammer F, et al. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 2018;39(1):70–79.
   PubMed Web of Science ®Google Scholar
• Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013;21(7):350–358.
   PubMed Web of Science ®Google Scholar
• Thompson CP, Lourenco J, Walters AA, et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun. 2018;9(1):3859.
   PubMedGoogle Scholar
• Sagawa H, Ohshima A, Kato I, et al. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol. 1996;77(Pt 7):1483–1487.
   PubMedGoogle Scholar
• Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189–202.
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87(12):6542–6550.
   PubMed Web of Science ®Google Scholar
• Egorov AE. The challenges of creating a universal influenza vaccine. Mir J. 2016;3(1):31–41.
   Google Scholar